Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Portfolio Pulse from Vandana Singh
Ginkgo Bioworks has expanded its partnership with Google Cloud to introduce two AI tools aimed at accelerating drug development. These tools, a protein large language model and a model API, leverage AI and proprietary data to enhance therapeutic discovery. The collaboration with Google Cloud and the development of AlphaFold 3 by Google DeepMind are key components of this initiative.
September 17, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ginkgo Bioworks has launched two AI tools in partnership with Google Cloud to accelerate drug development, leading to an 11.60% increase in its stock price.
The launch of AI tools in collaboration with Google Cloud is a significant development for Ginkgo Bioworks, enhancing its capabilities in drug development. This has positively impacted its stock price, indicating strong market confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Google Cloud's partnership with Ginkgo Bioworks to develop AI tools for drug development highlights its growing influence in the biotech sector.
Google Cloud's involvement in developing AI tools for drug development with Ginkgo Bioworks showcases its strategic expansion into the biotech industry, potentially enhancing its market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 70
POSITIVE IMPACT
Alphabet's Google Cloud division collaborates with Ginkgo Bioworks to introduce AI tools for drug development, reinforcing its role in biotech innovation.
Alphabet's Google Cloud is enhancing its presence in the biotech sector through its partnership with Ginkgo Bioworks, which could positively influence its stock by showcasing its innovative capabilities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 70